Matrix Metalloproteinase 13

"Matrix Metalloproteinase 13" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A secreted matrix metalloproteinase that plays a physiological role in the degradation of extracellular matrix found in skeletal tissues. It is synthesized as an inactive precursor that is activated by the proteolytic cleavage of its N-terminal propeptide.

Descriptor ID	D053509
MeSH Number(s)	D08.811.277.656.300.480.205.363 D08.811.277.656.300.480.525.700.550 D08.811.277.656.675.374.205.363 D08.811.277.656.675.374.525.700.550 D12.644.276.848.550 D12.776.467.836.550
Concept/Terms	Matrix Metalloproteinase 13 Matrix Metalloproteinase 13 Metalloproteinase 13, Matrix Matrix Metalloproteinase-13 Metalloproteinase-13, Matrix MMP13 Metalloproteinase Metalloproteinase, MMP13 MMP-13 Metalloproteinase MMP 13 Metalloproteinase Metalloproteinase, MMP-13 Collagenase-3 Collagenase 3

Below are MeSH descriptors whose meaning is more general than "Matrix Metalloproteinase 13".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Hydrolases [D08.811.277]
Peptide Hydrolases [D08.811.277.656]
Endopeptidases [D08.811.277.656.300]
Metalloendopeptidases [D08.811.277.656.300.480]
Collagenases [D08.811.277.656.300.480.205]
Matrix Metalloproteinase 13 [D08.811.277.656.300.480.205.363]
Matrix Metalloproteinases [D08.811.277.656.300.480.525]
Matrix Metalloproteinases, Secreted [D08.811.277.656.300.480.525.700]
Matrix Metalloproteinase 13 [D08.811.277.656.300.480.525.700.550]
Metalloproteases [D08.811.277.656.675]
Metalloendopeptidases [D08.811.277.656.675.374]
Collagenases [D08.811.277.656.675.374.205]
Matrix Metalloproteinase 13 [D08.811.277.656.675.374.205.363]
Matrix Metalloproteinases [D08.811.277.656.675.374.525]
Matrix Metalloproteinases, Secreted [D08.811.277.656.675.374.525.700]
Matrix Metalloproteinase 13 [D08.811.277.656.675.374.525.700.550]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Intercellular Signaling Peptides and Proteins [D12.644.276]
Matrix Metalloproteinases, Secreted [D12.644.276.848]
Matrix Metalloproteinase 13 [D12.644.276.848.550]
Proteins [D12.776]
Intercellular Signaling Peptides and Proteins [D12.776.467]
Matrix Metalloproteinases, Secreted [D12.776.467.836]
Matrix Metalloproteinase 13 [D12.776.467.836.550]

Below are MeSH descriptors whose meaning is more specific than "Matrix Metalloproteinase 13".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Matrix Metalloproteinase 13" by people in this website by year, and whether "Matrix Metalloproteinase 13" was a major or minor topic of these publications.

Bar chart showing 14 publications over 8 distinct years, with a maximum of 3 publications in 2006

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	0	1	1
2006	1	2	3
2007	1	1	2
2009	0	2	2
2010	1	1	2
2011	0	2	2
2018	1	0	1
2020	0	1	1

Below are the most recent publications written about "Matrix Metalloproteinase 13" by people in Profiles.

Angel PM, Bruner E, Bethard J, Clift CL, Ball L, Drake RR, Feghali-Bostwick C. Extracellular matrix alterations in low-grade lung adenocarcinoma compared with normal lung tissue by imaging mass spectrometry. J Mass Spectrom. 2020 Apr; 55(4):e4450.

View in: PubMed
Parrott ME, Aljrbi E, Biederman DL, Montalvo RN, Barth JL, LaVoie HA. Maternal cardiac messenger RNA expression of extracellular matrix proteins in mice during pregnancy and the postpartum period. Exp Biol Med (Maywood). 2018 11; 243(15-16):1220-1232.

View in: PubMed
Dixon JA, Gorman RC, Stroud RE, Mukherjee R, Meyer EC, Baker NL, Morita M, Hamamoto H, Ryan LP, Gorman JH, Spinale FG. Targeted regional injection of biocomposite microspheres alters post-myocardial infarction remodeling and matrix proteolytic pathways. Circulation. 2011 Sep 13; 124(11 Suppl):S35-45.

View in: PubMed
Rigsby CS, Ergul A, Portik Dobos V, Pollock DM, Dorrance AM. Effects of spironolactone on cerebral vessel structure in rats with sustained hypertension. Am J Hypertens. 2011 Jun; 24(6):708-15.

View in: PubMed
Sachidanandam K, Portik-Dobos V, Kelly-Cobbs AI, Ergul A. Dual endothelin receptor antagonism prevents remodeling of resistance arteries in diabetes. Can J Physiol Pharmacol. 2010 Jun; 88(6):616-21.

View in: PubMed
Akhtar N, Rasheed Z, Ramamurthy S, Anbazhagan AN, Voss FR, Haqqi TM. MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes. Arthritis Rheum. 2010 May; 62(5):1361-71.

View in: PubMed
Rasheed Z, Anbazhagan AN, Akhtar N, Ramamurthy S, Voss FR, Haqqi TM. Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes. Arthritis Res Ther. 2009; 11(3):R71.

View in: PubMed
Sachidanandam K, Hutchinson JR, Elgebaly MM, Mezzetti EM, Dorrance AM, Motamed K, Ergul A. Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1. Am J Physiol Regul Integr Comp Physiol. 2009 Apr; 296(4):R952-9.

View in: PubMed
Hellman NE, Spector J, Robinson J, Zuo X, Saunier S, Antignac C, Tobias JW, Lipschutz JH. Matrix metalloproteinase 13 (MMP13) and tissue inhibitor of matrix metalloproteinase 1 (TIMP1), regulated by the MAPK pathway, are both necessary for Madin-Darby canine kidney tubulogenesis. J Biol Chem. 2008 Feb 15; 283(7):4272-82.

View in: PubMed
Madhavan S, Anghelina M, Sjostrom D, Dossumbekova A, Guttridge DC, Agarwal S. Biomechanical signals suppress TAK1 activation to inhibit NF-kappaB transcriptional activation in fibrochondrocytes. J Immunol. 2007 Nov 01; 179(9):6246-54.

View in: PubMed

People

Explore

Similar Concepts

Top Journals